Edding Genor Group Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, and Crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for breast cancer; and GB492, a stimulator of interferon genes combined with GB226, currently under Phase 1/2 clinical trial to treat solid tumours. It also develops GB226, which is in Phase III clinical trial; GB261, which is in Phase I/II clinical trial for NHL; and GB263T that is in Phase I/II clinical trial for NSCLC. In addition, the company develops GB221, which is in Phase III clinical trial for HER2+ 1L/2L+ mBC; GB223 that is in Phase I clinical trial for GCTB, PMO; GB241 that is in Phase III clinical trial for 1L DLBCL; and GB251, which is in Phase I clinical trial for HER2+ 1L/2L+ mBC. Further, the company's product candidates that are in pre-clinical trials include GB262, GB264, GB266, GB267, and GB268 for cancer treatment. The company was formerly known as Genor Biopharma Holdings Limited and changed its name to Edding Genor Group Holdings Limited in December 2025. The company was founded in 2007 and is headquartered in Shanghai, China.